Synthesis and in vitro biological evaluation of carbonyl group-containing inhibitors of vesicular acetylcholine transporter.

To identify selective high-affinity inhibitors of the vesicular acetylcholine transporter (VAChT), we have interposed a carbonyl group between the phenyl and piperidyl groups of the prototypical VAChT ligand vesamicol and its more potent analogues benzovesamicol and 5-aminobenzovesamicol. Of 33 compounds synthesized and tested, 6 display very high affinity for VAChT (K(i), 0.25-0.66 nM) and greater than 500-fold selectivity for VAChT over sigma(1) and sigma(2) receptors. Twelve compounds have high affinity (K(i), 1.0-10 nM) and good selectivity for VAChT. Furthermore, 3 halogenated compounds, namely, trans-3-[4-(4-fluorobenzoyl)piperidinyl]-2-hydroxy-1,2,3,4-tetrahydronaphthalene (28b) (K(i) = 2.7 nM, VAChT/sigma selectivity index = 70), trans-3-[4-(5-iodothienylcarbonyl)piperidinyl]-2-hydroxy-1,2,3,4-tetrahydronaphthalene (28h) (K(i) = 0.66 nM, VAChT/sigma selectivity index = 294), and 5-amino-3-[4-(p-fluorobenzoyl)piperidinyl]-2-hydroxy-1,2,3,4,-tetrahydronaphthalene (30b) (K(i) = 2.40 nM, VAChT/sigma selectivity index = 410) display moderate to high selectivity for VAChT. These three compounds can be synthesized with the corresponding radioisotopes so as to serve as PET/SPECT probes for imaging the VAChT in vivo.

[1]  R. Koeppe,et al.  Positron emission tomography imaging of (2R,3R)-5-[(18)F]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter. , 2009, Nuclear medicine and biology.

[2]  R. Mach,et al.  Synthesis and in vitro and in vivo evaluation of 18F-labeled positron emission tomography (PET) ligands for imaging the vesicular acetylcholine transporter. , 2009, Journal of medicinal chemistry.

[3]  K. Ishiwata,et al.  The potential of (−)‐o‐[11C]methylvesamicol for diagnosing cholinergic deficit dementia , 2008, Synapse.

[4]  J. Seibyl,et al.  Comparison of Noninvasive Quantification Methods of in Vivo Vesicular Acetylcholine Transporter Using [123I]-IBVM SPECT Imaging , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  J. Dartigues,et al.  In vivo SPECT imaging of vesicular acetylcholine transporter using [123I]-IBVM in early Alzheimer's disease , 2008, NeuroImage.

[6]  M. Scheunemann,et al.  A new 18F-labeled fluoroacetylmorpholino derivative of vesamicol for neuroimaging of the vesicular acetylcholine transporter. , 2008, Nuclear medicine and biology.

[7]  R. Mach,et al.  Fluorine-18-labeled benzamide analogues for imaging the sigma2 receptor status of solid tumors with positron emission tomography. , 2007, Journal of medicinal chemistry.

[8]  A. Terry,et al.  Time-Dependent Cognitive Deficits Associated with First and Second Generation Antipsychotics: Cholinergic Dysregulation as a Potential Mechanism , 2007, Journal of Pharmacology and Experimental Therapeutics.

[9]  C. Guatimosim,et al.  Mice Deficient for the Vesicular Acetylcholine Transporter Are Myasthenic and Have Deficits in Object and Social Recognition , 2006, Neuron.

[10]  H. Soreq,et al.  Virtues and woes of AChE alternative splicing in stress-related neuropathologies , 2006, Trends in Neurosciences.

[11]  R. Mach,et al.  Carbon-11 labeled σ2 receptor ligands for imaging breast cancer , 2005 .

[12]  R. Mach,et al.  [3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: a novel sigma-2 receptor probe. , 2005, European journal of pharmacology.

[13]  S. Kish,et al.  Brain vesicular acetylcholine transporter in human users of drugs of abuse , 2004, Synapse.

[14]  A. Graybiel,et al.  Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia , 1999, Neuroscience.

[15]  R. Mach,et al.  Hydroxylated decahydroquinolines as ligands for the vesicular acetylcholine transporter: synthesis and biological evaluation. , 1999, Journal of medicinal chemistry.

[16]  T. Kitamoto,et al.  Structure and Organization of the DrosophilaCholinergic Locus* , 1998, The Journal of Biological Chemistry.

[17]  R. Mach,et al.  N-hydroxyalkyl derivatives of 3 beta-phenyltropane and 1-methylspiro[1H-indoline-3,4'-piperidine]: vesamicol analogues with affinity for monoamine transporters. , 1997, Journal of medicinal chemistry.

[18]  J. Dedman,et al.  Molecular characterization of the mouse vesicular acetylcholine transporter gene , 1997, Neuroreport.

[19]  K. Ajiki,et al.  Localization of two cholinergic markers, choline acetyltransferase and vesicular acetylcholine transporter in the central nervous system of the rat: in situ hybridization histochemistry and immunohistochemistry , 1997, Journal of Chemical Neuroanatomy.

[20]  D. Holtzman,et al.  Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Minoshima,et al.  In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease , 1996, Annals of neurology.

[22]  D. Kuhl,et al.  Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol. , 1996, Journal of medicinal chemistry.

[23]  M. Schäfer,et al.  Visualization of the vesicular acetylcholine transporter in cholinergic nerve terminals and its targeting to a specific population of small synaptic vesicles. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Yi,et al.  Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesicles , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[25]  T. Bonner,et al.  Molecular biology of the vesicular ACh transporter , 1995, Trends in Neurosciences.

[26]  R. Mach,et al.  Vesamicol analogues as sigma ligands. Molecular determinants of selectivity at the vesamicol receptor. , 1995, Biochemical pharmacology.

[27]  R. Edwards,et al.  Molecular cloning of a putative vesicular transporter for acetylcholine. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Bonner,et al.  Functional identification of a vesicular acetylcholine transporter and its expression from a "cholinergic" gene locus. , 1994, The Journal of biological chemistry.

[29]  C. Foulon,et al.  Spirovesamicols: conformationally restricted analogs of 2-(4-phenylpiperidino)cyclohexanol (vesamicol, AH5183) as potential modulators of presynaptic cholinergic function. , 1994, Journal of medicinal chemistry.

[30]  N Butters,et al.  Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia. , 1994, Archives of neurology.

[31]  T. Bonner,et al.  Cloning and expression of the vesamicol binding protein from the marine ray Torpedo , 1994, FEBS letters.

[32]  G. Rogers,et al.  Kinetic and equilibrium characterization of vesamicol receptor-ligand complexes with picomolar dissociation constants. , 1993, Molecular pharmacology.

[33]  P. Dudchenko,et al.  Interactions between the effects of basal forebrain lesions and chronic treatment with MDL 26,479 on learning and markers of cholinergic transmission , 1993, Brain Research.

[34]  S. Efange,et al.  Nonsymmetrical bipiperidyls as inhibitors of vesicular acetylcholine storage. , 1993, Journal of medicinal chemistry.

[35]  S. Parsons,et al.  The pharmacology of vesamicol: an inhibitor of the vesicular acetylcholine transporter. , 1992, General pharmacology.

[36]  B. E. Evans,et al.  Orally active, nonpeptide oxytocin antagonists. , 1992, Journal of medicinal chemistry.

[37]  B Carragher,et al.  Three-Dimensional Analysis of the Relationship Between Synaptic Pathology and Neuropil Threads in Alzheimer Disease , 1992, Journal of neuropathology and experimental neurology.

[38]  E. Masliah,et al.  Localization of amyloid precursor protein in GAP43-immunoreactive aberrant sprouting neurites in Alzheimer's disease , 1992, Brain Research.

[39]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[40]  I. G. Marshall,et al.  α-Adrenoceptor blocking properties of vesamicol , 1991 .

[41]  S. Efange,et al.  Acyclic analogues of 2-(4-phenylpiperidino)cyclohexanol (vesamicol): conformationally mobile inhibitors of vesicular acetylcholine transport. , 1991, Journal of medicinal chemistry.

[42]  Y. Agid,et al.  Choline acetyltransferase activity and [ 3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions , 1990, Neuroscience.

[43]  S. Kish,et al.  [3H]Vesamicol binding in human brain cholinergic deficiency disorders , 1990, Neuroscience Letters.

[44]  S. DeKosky,et al.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity , 1990, Annals of neurology.

[45]  Stephen W. Scheff,et al.  Quantitative assessment of cortical synaptic density in Alzheimer's disease , 1990, Neurobiology of Aging.

[46]  G. Rogers,et al.  Synthesis, in vitro acetylcholine-storage-blocking activities, and biological properties of derivatives and analogues of trans-2-(4-phenylpiperidino)cyclohexanol (vesamicol). , 1989, Journal of medicinal chemistry.

[47]  S. Snyder,et al.  Structural determinants of sigma receptor affinity. , 1987, Molecular pharmacology.

[48]  P. Davies,et al.  Recent advances in the neurochemistry of Alzheimer's disease. , 1987, The Journal of clinical psychiatry.

[49]  C. Altar,et al.  Quantitative autoradiography of brain binding sites for the vesicular acetylcholine transport blocker 2-(4-phenylpiperidino)cyclohexanol (AH5183). , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[50]  I. G. Marshall,et al.  Studies on the blocking action of 2‐(4‐phenyl piperidino) cyclohexanol (AH5183) , 1970, British journal of pharmacology.

[51]  M. Scheunemann,et al.  Neuroimaging of the vesicular acetylcholine transporter by a novel 4-[18F]fluoro-benzoyl derivative of 7-hydroxy-6-(4-phenyl-piperidin-1-yl)-octahydro-benzo[1,4]oxazines. , 2009, Nuclear medicine and biology.

[52]  M. Schäfer,et al.  Distribution of the vesicular acetylcholine transporter (VAChT) in the central and peripheral nervous systems of the rat , 2007, Journal of Molecular Neuroscience.

[53]  M. Schäfer,et al.  Human and monkey cholinergic neurons visualized in paraffin-embedded tissues by immunoreactivity for VAChT, the vesicular acetylcholine transporter , 2007, Journal of Molecular Neuroscience.

[54]  S. Parsons,et al.  Acetylcholine transport, storage, and release. , 1993, International review of neurobiology.

[55]  C. Altar,et al.  [3H]vesamicol binding in brain: Autoradiographic distribution, pharmacology, and effects of cholinergic lesions , 1988, Synapse.